-

ProPath Expands Services on East Coast Partnering with New England Tissue Issue (NETI)

DALLAS--(BUSINESS WIRE)--ProPath, the largest 100% physician-owned pathology practice in the United States, announced today that New England Tissue Issue (NETI), a dermatopathology practice in Fall River, MA, has joined the ProPath family of companies. This strategic combination adds to ProPath’s talented team of physicians and staff while providing NETI’s clients and patients with access to a broader range of diagnostic services and resources. ProPath looks forward to growing the NETI facilities to serve more patients throughout the Northeast and nurturing the culture of service and quality established by NETI’s founders.

“We are thrilled to join forces with the physicians and other team members of NETI. Their quality and patient focus made this partnership an obvious choice as a way to grow our combined practices. Culture and trust are the cornerstones of any partnership and we share those in every way,” said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath.

“We wanted a partner that focused on patients first and maintained not just 100% physician ownership, but 100% physician control. Of all the potential partners we considered, only ProPath could provide that. They ticked every box and were the clear option to help us serve more patients even better,” said Erin O’Leary, M.D., co-founder of NETI.

NETI co-founder Todd Vinovrski, M.D. said, “Partnering with ProPath will allow us to continue caring for our patients and clients while also adding tremendous depth to our services and expertise. Knowing that we will now have access to the best esoteric testing available and to broader administrative support will allow us to focus even more on our patients.”

The combined practices will include over 174 million covered lives in nearly every state in the country. The partnership will allow 8 million patients from NETI’s catchment area in-network access to ProPath’s esoteric testing creating faster service with premium quality.

Dr. Roberts continued, "ProPath frequently finds itself as the best and only true physician-owned option for practices that want to maintain control but also want the diversification, strength in numbers, resources, expertise and infrastructure of a much larger organization. We are proud to carry that banner for independent groups and to provide an option in lieu of ceding control to outside owners."

About ProPath

ProPath is the largest, nationwide, 100% physician-owned pathology practice in the United States. Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries. Its 500 employees reside in 10 states and staff lab facilities in two states. For 54 years, ProPath’s mission has been to provide patient-centered, high quality and effective medical diagnostics, prognostics and research that creates better patient outcomes.

Contacts

Scott Rupnow
Chief Commercial Officer
214-237-1661

ProPath


Release Summary
ProPath Expands Services on East Coast Partnering with New England Tissue Issue (#NETI).
Release Versions

Contacts

Scott Rupnow
Chief Commercial Officer
214-237-1661

More News From ProPath

ProPath Earns 2021-22 Great Place to Work Certification™

DALLAS--(BUSINESS WIRE)--ProPath Earns 2021-22 Great Place to Work Certification...

ProPath Appoints Soft Tissue Tumor Expert, Julia A. Bridge, M.D., as Director of Cytogenetics and FISH

DALLAS--(BUSINESS WIRE)--ProPath, the largest fully physician-owned pathology practice in the United States, today announced that Julia A. Bridge, M.D., a board-certified pathologist and geneticist with an extensive medical career and expertise in solid tumor molecular testing, has joined the ProPath team. Dr. Bridge, who recently directed the Molecular Pathology Research Division at the Translational Genomics Research Institute in Phoenix, AZ, will be directing ProPath’s fluorescence in situ h...

ProPath Adds New Test for the Detection of Synovial Sarcoma

DALLAS--(BUSINESS WIRE)--ProPath’s Immunohistochemistry (IHC) laboratory has obtained a significant new addition to its library of over 300 antibody tests. Cary J. Buresh, M.D., ProPath’s Director of Immunohistochemistry, stated, “I am happy to announce the addition of SS18-SSX to our antibody library. It is a fusion-specific antibody that is highly sensitive (95%) and specific (100%) for the detection of synovial sarcoma.” Synovial sarcoma is a rare form of cancer found in different types of s...
Back to Newsroom